Cubist’s Zerbaxa Challenge Will Be Lack Of Superiority Claim
The biotech and its acquirer Merck laud the approval of another antibiotic, but its failure to gain superiority in the label puts Zerbaxa at a disadvantage to currently marketed products.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.